Article Text

Download PDFPDF
Clinical round-up
  1. Emily Chung1,
  2. Sophie Herbert2
  1. 1 Department of Sexual Health and HIV, Mortimer Market Centre, London, UK
  2. 2 Sexual Health, Ashwood Centre, Kettering, UK
  1. Correspondence to Dr Emily Chung, Department of Sexual Health and HIV, Mortimer Market Centre, London WC1E 6JB, UK; e.chung{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Hepatic steatosis and ‘return to health’ in HIV

Chronic liver disease and hepatic steatosis are increasingly problematic in the HIV-infected population. Hepatic steatosis is mostly associated with metabolic risk factors and the aim of this cross-sectional prospective study1 was to examine the prevalence and risk factors for severe hepatic steatosis in a large cohort of patients with HIV monoinfection.

A total of 364 patients were included: 78% male, 76% Caucasian with a mean age of 46. Metabolic blood tests and HIV disease markers were performed alongside measurement of controlled attenuation parameter (CAP), measuring the degree of ultrasound attenuation by hepatic fat by fibroscan. A total of 287 (79%) were HIV monoinfected and 95% were on antiretrovirals with 83% having undetectable HIV viral loads.

Significant hepatic steatosis defined as CAP </238 dB/m was common and observed in 41%. More severe steatosis was observed in patients with longer duration of known HIV infection (9 (0–26) vs 7 (0–29) years, p=0.019) but detectable HIV viral load did not have a statistically …

View Full Text


  • Contributors EC selected and wrote the manuscript and SH reviewed the manuscript.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.